Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children

@inproceedings{Nji2014RandomizedNA,
  title={Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children},
  author={Akindeh Mbuh Nji and Innocent M Ali and Marcel N Moyeh and Eric-Oliver Ngongang and Aristide M Ekollo and Jean-Paul Chedjou and Valentine N Ndikum and Marie Solange Evehe and Guenter Froeschl and Christian Heumann and U. Mansmann and Olumide A. T. Ogundahunsi and Wilfred F Mbacham},
  booktitle={Malaria Journal},
  year={2014}
}
BackgroundArtemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Cochrane Column.

VIEW 2 EXCERPTS
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

de la Santé Publique: plan stratégique national de lutte contre le paludisme 2011–2015

MOH. Ministèr
  • Cameroon: Ministry of Public Health;
  • 2012
VIEW 1 EXCERPT

Safety and efficacy of dihydroartemisinin- piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children

M Nambozi, J-P Van Geertruyden, +3 authors M Mulenga
  • Malar J. 2011;10:50
  • 2011
VIEW 2 EXCERPTS

report 2011

WHO. World Malari
  • Geneva: World Health Organization;
  • 2011
VIEW 2 EXCERPTS